Passage Bio, Inc. (PASG) has disclosed a new risk, in the Innovation / R&D category.
Passage Bio, Inc. faces significant business risk as their prospects hinge on the development and commercialization of PBFT02, their lone clinical stage product candidate. The path to market for PBFT02 is fraught with regulatory hurdles, requiring approval from the FDA and equivalent bodies abroad—a process that is both costly and uncertain. Should PBFT02 fail to obtain necessary approvals, experience delays, or not gain market acceptance, the impact on Passage Bio’s financial stability and operational outcomes could be severely detrimental. The company’s reliance on this single candidate underscores a precarious position that could lead to adverse financial repercussions if not navigated successfully.
Overall, Wall Street has a Moderate Buy consensus rating on PASG stock based on 2 Buys.
To learn more about Passage Bio, Inc.’s risk factors, click here.
